SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Som...
11 Décembre 2012 - 4:31PM
Business Wire
Levi & Korsinsky is investigating the Board of Directors of
Somaxon Pharmaceuticals, Inc. (“Somaxon” or the “Company”)
(NasdaqCM: SOMX) for possible breaches of fiduciary duty and other
violations of state law in connection with the sale of the Company
to Pernix Therapeutics Holdings, Inc. (NYSE MKT: PTX).
Click here to learn more about the investigation:
http://zlk.9nl.com/somaxon-pharmaceuticals-somx/, or call:
877-363-5972. There is no cost or obligation to you.
Under the terms of the transaction, Somaxon shareholders will
receive an aggregate consideration equal to $25 million in Pernix
common stock. The number of shares of Pernix stock issued will be
based on the volume-weighted average price of Pernix’s common stock
in the 30 day period prior to the merger’s closing, representing a
value of between $6.00 and $9.00 per share. The investigation
concerns whether the Somaxon Board of Directors breached their
fiduciary duties to stockholders by failing to adequately shop the
Company before entering into this agreement with Pernix
Therapeutics Holdings, Inc.
If you own common stock in Somaxon and wish to obtain additional
information, please contact Joseph E. Levi, Esq. either via email
at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free:
(877) 363-5972, or visit
http://zlk.9nl.com/somaxon-pharmaceuticals-somx/.
Levi & Korsinsky is a national firm with offices in New York
and Washington D.C. The firm has extensive expertise in prosecuting
securities litigation involving financial fraud, representing
investors throughout the nation in securities and shareholder
lawsuits. Attorney advertising. Prior results do not guarantee
similar outcomes.
Somaxon (NASDAQ:SOMX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Somaxon (NASDAQ:SOMX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Somaxon Pharmaceuticals, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Levi & Korsinsky, LLP